About Delix
  • innovative and inclusive

    Delix is leading a mental health revolution

    Based on the discovery of a novel class of neuroplasticity-promoting therapeutics known as psychoplastogens, we are building a world class CNS company on a mission to broaden patient access to safe, fast-acting, and long-lasting medicines for many of the leading causes of disability worldwide.

    our team
  • novel mechanism of plasticity

    The Delix neuroplasticity platform

    Delix is pushing the frontiers of neuroplasticity research to achieve selective re-wiring of pathological neural circuits.  As dysfunctional neural circuits are at the heart of all brain disorders, the Delix platform has broad potential to address a range of diseases including treatment-resistant depression, substance use disorder, PTSD, cognitive impairment in schizophrenia, neurodegeneration, and many others. 

    our science
  • expanding the promise of psychoplastogens

    Delix has a rapidly growing therapeutic pipeline

    Using our platform, we are developing a pipeline of distinct therapeutic assets tailored to specific disease indications.  These include novel molecules inspired by the structures of psychedelics that positively re-wire pathological neural circuitry, but without the hallucinogenic and other side effects that have prevented ketamine and psychedelics from being deployed at scale.

    our publications
  • unique compound library

    The Delix discovery engine

    Our scientific rigor has enabled us to build broad screening capabilities that include gold standard assays as well as innovative, cutting-edge technologies. With several partners and alliances, we are advancing over 500 compounds based on > 8 unique chemical scaffolds.  Our first two assets are on track to be in the clinic in 2022, with several additional compounds not far behind.

    our news